UBC and Accredo® Specialty Pharmacy Provide Integrated Support for Gilotrif™ (afatinib) tablets

UBC and Accredo® Specialty Pharmacy Provide Integrated Support for Gilotrif™ (afatinib) tablets

UBC and Accredo® Specialty Pharmacy Provide Integrated Support for Gilotrif™ (afatinib) tablets

UBC and Accredo Specialty Pharmacy will play a significant role in dispensing GILOTRIF, helping patients who are prescribed GILOTRIF gain access to the medicine, and providing those patients with clinical support through Boehringer Ingelheim’s comprehensive patient support program – named Solutions Plus™

As the exclusive specialty pharmacy for GILOTRIF, Accredo has been chosen for its ability to provide specialized support programs for cancer patients.  Partnering with Accredo, UBC has been selected to manage GILOTRIF’s Reimbursement Services and Patient Assistance Program under the Solutions Plus™ program. 

GILOTRIF was approved by the U.S. Food and Drug Administration (FDA) on July 12, 2013, as a new first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L158R) substitution mutations as detected by an FDA-approved test.  Safety and efficacy of GILOTRIF have not been established in patients whose tumors have other EGFR mutations.

Recognizing that patients with NSCLC with common EGFR mutations require complementary support, Accredo will manage two Solutions PlusTM programs to help patients prescribed GILOTRIF access to therapy quickly and with the assurance of flexibility to both prescription dose and duration.  GILOTRIF Pledge™ allows for a patient and participating payer refund for the first month of therapy if eligible patients discontinue before the first refill.  And, GILOTRIF Dose Exchange™ facilitates transition within one month to new dosage if needed for eligible patients, eliminating duplicative copay and payor costs.

Efficient, affordable and specialized support for complex, chronic conditions involves extensive coordination from a single source. UBC and Accredo are proud to partner with Boehringer Ingelheim to deliver streamlined services for patients prescribed GILOTRIF.